Previous 10 | Next 10 |
Annovis Bio (ANVS) ticks 18% higher in premarket, after the company announced the publication of peer-reviewed data demonstrating the ability of its lead candidate, ANVS401 (Posiphen), to improve axonal transport, the information highway of nerve cells.Currently the product is ...
Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association Study a dds f urther v alidation that Annovis’ l ead c ompound is the only drug to improve axonal transport, the informati...
Annovis Bio (NYSEMKT: ANVS ) announces dosing of the first three patients in its new Phase 2a clinical trial targeting early Alzheimer’s disease (AD) and Parkinson’s disease (PD). More news on: Annovis Bio, Inc., Healthcare stocks news, Read more ...
BERWYN, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced dosing of the first three patients...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
LOS ANGELES, CA / ACCESSWIRE / August 25, 2020 / Annovis Bio Inc. (NYSE American:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that it will be presenting at the LD 500 invest...
Moving past COVID-19 disruptions, Annovis Bio (NYSEMKT: ANVS ) has restarted recruitment in a 24-subject Phase 2a clinical trial evaluating lead candidate ANVS401 in patients with early Alzheimer's disease (AD). More news on: Annovis Bio, Inc., Healthcare stocks news, Stocks on ...
BERWYN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, is pleased to announce it has restarted patient rec...
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...